Merck & Co., Inc. Isentress/Isentress HD revenue
Isentress/Isentress HD revenue at Merck & Co., Inc. came to $52.0M for the quarter to 30 Sep 2026, down 36.6% from a year earlier.
As Merck & Co., Inc. reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 4 Nov 2026.
By quarter
| Period ending | Isentress/Isentress HD revenue | Change on a year | Filed |
|---|---|---|---|
| 30 Sep 2026 | $52.0M | down 36.6% | 4 Nov 2026 |
| 30 Jun 2026 | $60.0M | down 30.2% | 7 Aug 2026 |
| 31 Mar 2026 | $59.0M | down 34.4% | 4 May 2026 |
| 31 Dec 2025 | $67.0M | down 27.2% | 24 Feb 2026 |
| 30 Sep 2025 | $82.0M | down 19.6% | 5 Nov 2025 |
| 30 Jun 2025 | $86.0M | down 3.4% | 5 Aug 2025 |
| 31 Mar 2025 | $90.0M | down 18.9% | 2 May 2025 |
| 31 Dec 2024 | $92.0M | down 13.2% | 25 Feb 2025 |
| 30 Sep 2024 | $102.0M | down 14.3% | 6 Nov 2024 |
| 30 Jun 2024 | $89.0M | down 34.6% | 5 Aug 2024 |
| 31 Mar 2024 | $111.0M | down 9.8% | 3 May 2024 |
| 31 Dec 2023 | $106.0M | down 36.5% | 26 Feb 2024 |
| 30 Sep 2023 | $119.0M | down 26.1% | 3 Nov 2023 |
| 30 Jun 2023 | $136.0M | down 7.5% | 7 Aug 2023 |
| 31 Mar 2023 | $123.0M | down 22.2% | 5 May 2023 |
| 31 Dec 2022 | $167.0M | down 6.7% | 24 Feb 2023 |
| 30 Sep 2022 | $161.0M | down 14.8% | 3 Nov 2022 |
| 30 Jun 2022 | $147.0M | down 23.4% | 5 Aug 2022 |
| 31 Mar 2022 | $158.0M | down 24.4% | 5 May 2022 |
| 31 Dec 2021 | $179.0M | down 15.2% | 25 Feb 2022 |
| 30 Sep 2021 | $189.0M | down 7.8% | 5 Nov 2021 |
| 30 Jun 2021 | $192.0M | down 2.0% | 9 Aug 2021 |
| 31 Mar 2021 | $209.0M | down 14.7% | 5 May 2021 |
| 31 Dec 2020 | $211.0M | down 5.4% | 25 Feb 2021 |
| 30 Sep 2020 | $205.0M | down 18.0% | 5 Nov 2020 |
| 30 Jun 2020 | $196.0M | down 20.6% | 5 Aug 2020 |
| 31 Mar 2020 | $245.0M | down 3.9% | 6 May 2020 |
| 31 Dec 2019 | $223.0M | down 20.4% | 26 Feb 2020 |
| 30 Sep 2019 | $250.0M | down 9.1% | 5 Nov 2019 |
| 30 Jun 2019 | $247.0M | down 19.0% | 6 Aug 2019 |
| 31 Mar 2019 | $255.0M | down 9.3% | 8 May 2019 |
| 31 Dec 2018 | $280.0M | — | 27 Feb 2019 |
| 30 Sep 2018 | $275.0M | down 11.3% | 6 Nov 2018 |
| 30 Jun 2018 | $305.0M | up 8.2% | 7 Aug 2018 |
| 31 Mar 2018 | $281.0M | — | 8 May 2018 |
| 30 Sep 2017 | $310.0M | — | 7 Nov 2017 |
| 30 Jun 2017 | $282.0M | — | 8 Aug 2017 |
Definition
Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.
Other operating KPIs of Merck & Co., Inc.: Keytruda revenue · Gardasil/Gardasil 9 revenue · Livestock revenue · Keytruda Qlex revenue · ProQuad/M-M-R II/Varivax revenue · Winrevair revenue · Companion Animal revenue · Lynparza alliance revenue · Prevymis revenue · Welireg revenue · Lenvima alliance revenue · Capvaxive revenue · RotaTeq revenue · Vaxneuvance revenue · Janumet revenue · Januvia revenue · Ohtuvayre revenue · Reblozyl alliance revenue · Bridion revenue · Adempas/Verquvo alliance revenue · Zerbaxa revenue · Adempas revenue · Delstrigo revenue · Belsomra revenue · financial statements
Every KPI and segment of MRK, in the terminal.
Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.
